Clinical Trial

UGX202 Injection in Patients With Advanced Retinitis Pigmentosa

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.
Trial Details
NCT Number NCT07311863
Lead Sponsor Suzhou UgeneX Therapeutics Co., Ltd.
Collaborators: Eye & ENT Hospital of Fudan University
Conditions Retinitis Pigmentosa (RP)
Enrollment 6 participants
Start Date 2026-01
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-31